Pharma Firm booked for Rs 1,627 Crore Loan Fraud

A further probe into the matter is underway.

Police Arrest
Picture: Pixabay

Last Updated on January 2, 2022 by The Health Master

New Delhi: The Central Bureau of Investigation (CBI) said on Friday that it has registered a case based on a complaint from the Central Bank of India and other member banks against a Chandigarh-based private company for cheating the bank to the tune of Rs 1, 626.74 crore on the pretext of a loan.

The case was lodged against Parabolic Drugs Ltd; its managing director, Pranav Gupta; seven directors, Vineet Gupta, Deepali Gupta, Rama Gupta, Jagjit Singh Chahal, Sanjeev Kumar, Vandana Singla, and Ishrat Gill; and guarantors J.D. Gupta, T.N. Goyal, and Nirmal Bansal, and unknown public servants and private persons, as per the CBI.

The accused hatched a criminal conspiracy to cheat the bank on the pretext of loan. They committed forgery by using forged documents to avail loans. After obtaining the loan, they diverted the funds to other groups.

The bank employees also helped the accused in obtaining the loan, thus helping them commit the fraud. The CBI said that the bank employees were paid commission for helping the accused obtain the loan.

When the bank came to know about the irregularities, a department inquiry was initiated in which it was found that the loan was given on the basis of forged documents.

The bank then decided to approach the CBI, which lodged a case of cheating, formed a team and started an investigation.

On Friday, the agency conducted raids at 12 different locations in Chandigarh, Panchkula, Ludhiana, Faridabad and Delhi. The raids were conducted at the office and residential premises of the accused persons.

A senior CBI official said that the raids led to the recovery of incriminating documents, articles, and cash worth Rs 1.58 crore.

A further probe into the matter is underway.

Drug industry cheers FSSAI’s removal of ban on Methylcobalamin

USFDA gives tentative nod to Zydus Cadila for Pimavanserin capsules

Molnupiravir: A wonder drug or a limited star?

Meting for 19 FDCs permitted pre-1988 postponed

DCGI gives approval to Biological E for Corbevax

USFDA gives tentative nod to Amphastar Pharma for Vasopressin injection

NPPA fixes retail price of 2 formulations: December 2021

NPPA fixes retail price of 28 formulations: December 2021

NPPA extends price cap on liquid Medical Oxygen and Oxygen inhalation

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon

Enter your email address:

Delivered by FeedBurner